AC Immune and partner Roche reported that semorinemab significantly slowed cognitive decline in the Phase II LAURIET trial – the first anti-tau mAb to do so in Alzheimer's disease (AD) – but confusingly it failed the functional co-primary endpoint, as well as multiple secondary measures.
To provide FirstWord readers with rapid feedback on what the readout means for semorinemab and other tau-targeting AD programmes, we are hosting an expert call with a key opinion leader (KOL) next week.
Key topics that will be discussed during the call include, among other things… what stands out most about the top-line LAURIET readout; how impressive is semorinemab's statistical success on ADAS-Cog11; how disappointing is it that a functional benefit was not observed; does semorinemab's failure on the functional and several secondary endpoints raise questions about how real the effect is on ADAS-Cog11; any theories for the discordance on the two co-primary endpoints; what will you be most interested to see when detailed LAURIET data are presented; any theories for why semorinemab may have succeeded in mild-to-moderate AD after failing in prodromal-to-mild patients; how much of a breakthrough is this readout for anti-tau drug development in AD; what is your level of enthusiasm for tau-targeting therapies and how (if at all) has that changed due to the LAURIET findings; and which modalities targeting tau are you most optimistic and/or pessimistic about?
Ask the expert!
Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the prospects for anti-tau therapies including semorinemab.
We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.
As always, FirstWord Pharma would very much like to receive your feedback and suggestions.
To read more KOL Views articles, click here.